Imiphumela emibi yeTarceva nokuthi yini ongayenza ukulwa nayo
I-Tarceva (i-erlotinib) ngumuthi okhishwe umdlavuza ohloswe ukwelashwa umdlavuza osencane omncane wesifo samaphaphu kanye nesifo somdlavuza we-pancreatic (ngokuhambisana ne-gemcitabine chemotherapy). Isebenza ngokukhomba amaprotheni okuthiwa i-epidermal growth factor receptor (EGFR) ephikisayo ukukhula komakhalekhukhwini. Kuyinto imithi ngomlomo futhi kunqunywe kwifomu tablet.
I-Tarceva Imiphumela Emibi
Njengawo wonke umuthi womdlavuza, kungase kube nemiphumela emibi. Qinisekisa ukuxoxa nganoma yiziphi izimpawu zalawa nodokotela wakho uma kwenzeka. Imiphumela emibi kakhulu ye-Tarceva ifaka phakathi:
Rash nge-Tarceva
Ama-Rashes ahlobene noTarceva ngokuvamile avela ezinsukwini eziyishumi zokuqala ukwelashwa. Labo abathatha i-Tarceva kuhlanganiswe ne-gemcitabine bangakha ukuqhuma noma nini ngesikhathi sokwelashwa. I-Tarceva iqhuma ibheka njenge-acne noma isikhumba esomile futhi ingavela emzimbeni nasebusweni. Ivame ukuvela kusukela okhalweni phezulu. Kwabanye, ukuqhuma kungase kube mnandi noma uzizwe njengokushisa kwelanga kancane. Akubona bonke abantu abazokuthuthukisa ukuqhuma kwesikhumba kusuka eTarceva. Labo abahlakulela ukuqhuma ngokuvamile babika ukuthi bancedisa ngenkathi ukwelashwa kanti njengoba umthamo wehlisa.
Ucwaningo olwenziwe ngo-2007 lwathola ukuthi labo abahlakulela ukukhwabanisa ngenkathi bethatha iTarceva babe nemiphumela engcono kunalabo abangakwenzi. Akukhona ukuthi izidakamizwa azizange ziphumelele kulabo abangazange bahlasele, kodwa labo abakha ukuqhuma kwakungenzeka ukuthi bazuze.
Ngakho-ke, ngenkathi ukuhlaselwa okuhlobene nokusetshenziswa kweTarceva kubonakala kuhle kuma-oncologists, akusona isiqinisekiso.
Kubaluleke kakhulu ukuthi uvumele udokotela wakho wazi uma uqala ukuthuthukisa ukuqhuma. Ungasebenzisi noma yimiphi imithi yokwelashwa, ugweme ngisho nangaphezu kwekhalenda noma imithi yamagciwane. Xhumana nodokotela wakho kuqala.
Udokotela wakho angase anikeze i-antibiotics noma amanye amafutha ukuze kusize nge-rash. Abanye bangase bazuze ekwelapheni okwesikhashana, ngisho noma kungakapheli izinsuku ezimbalwa.
Kubalulekile ukuqaphela ukuthi ukukhwabanisa isikhumba esibi kakhulu kwenzeka ngesikhathi sokuhlolwa kwemitholampilo. Ingumphumela wecala oqhekeke kakhulu kakhulu oye wafaniswa noStevens-Johnsons syndrome, isimo esingaba yingozi esabangelwa ukusabela okunamandla kakhulu kumuthi.
Isifo sohudo ngeTarceva
Omunye umphumela ovamile ohlangene weTarceva uhudo. Ukukhathazeka ngesifo sohudo ukuthi kungabangela ukungcola, ngakho-ke ufuna ukuxoxa ngesimo nodokotela wakho. Ngenkathi ingavame ukulawulwa ngezidakamizwa ezingaphezu kuka- anti-diarrhea , thintana nodokotela wakho ngaphambi kokuba uthathe noma yini. Angase abe nezincomo ezithile eziphathelene nomkhiqizo nomthamo. Uma uhudo lwakho ludlulela noma alukwazi ukulawulwa ngemithi ephezulu, shayela udokotela wakho.
Ezinye Imiphumela Ezingavamile ZeTarceva
Eminye imiphumela emibi ejwayelekile yeTarceva ihlanganisa ukulahlekelwa ukudla, ukukhathala, ukucwenga, nokuhlanza. Khumbula njalo ukwazisa udokotela wakho nganoma yimiphi imiphumela emibi oyizwayo.
I-Tarreva Side Effects Rare
Ezilingo zomtholampilo, le mibi emibi engavamile kaTarceva yabonwa:
- ama-perforations emathumbu
- isifo sengculazi
- Ukulimala kwezinso / isibindi
- umonakalo emehlweni
Qinisekisa ukuthi unikeza udokotela wakho umlando wezempilo ophelele ohlanganisa yonke imithi yokwelapha, imithi ye-herbal, nemithi kadokotela oyithathayo. Izimo ezithile zingakwandisa ingozi yokuba nemiphumela emibi engavamile.
Khumbula ukuthi lezi yimiphumela emibi kakhulu engavamile. Uma ukhathazekile ngezingozi zale mibi, cocisana nodokotela wakho. Ngokubambisana, ungaxoxa ngezinzuzo ezihambisana nezingozi zokuthatha i-Tarceva.
Lapho Ukubiza Udokotela Wakho
Shayela udokotela wakho uma:
- ukuthuthukisa ukukhwehlela
- ukuzwa ukuphefumula kokuphefumula
- ukuzwa ukucasuka kweso
- Thuthukisa ukuqhuma kwesikhumba noma ukuqhuma kwakho kunzima
- unomkhuhlane
- ukuzwa ukuhlanza noma uhudo oludlulayo
Imithombo:
U-Erlotinib, i-MedlinePlus, i-US National Library of Medicine, ebuyekezwe 07/01/2009.
Wacker B, Nagrani T, Weinberg J, et al. Ukulingana phakathi kokuthuthukiswa kokuqapha nokusebenza kweziguli eziphathwa nge-epidermal growth factor receptor tyrosine kinase inhibitor erlotinib kwizifundo ezimbili zesigaba III esikhulu. I-Clin Cancer Res. 2007; 13 (13): 3913-3921.